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CHAPTER I
INTRODUCTION
Many plants produce chemicals that mimic or interact with hormone signals in
animals. The estrogen-like phytoestrogens are the most studied of all phytochemicals. In
general, phytoestrogens are weaker than the natural estrogen hormones found in humans
(Ford, et al., 2006) and animals or the very potent synthetic estrogens used in oral
contraceptives or other drugs. Exposure to phytoestrogens is mainly through diet from
such plants as herbs, seasonings, grains, vegetables, fruits, and alcohol (Burton and
Wells, 2002). The two most studied phytoestrogen groups are lignans and isoflavones.
We are exposed daily to variable amounts of phytoestrogens. Adults eating a vegetarian
diet or those taking dietary supplements containing phytoestrogens have high levels of
exposure (Setchell and Cassidy, 1999). Infants fed soy milk, their only source of
nutrition for the first few months of life, have the highest exposure level at ten times the
concentration of adult vegetarians. At present it is estimated that more than 15 percent of
infants in the United States are fed a soy based diet the first few months of life (Chen, et
al., 2005).
Studies suggest that phytoestrogens, such as genistein, may offer long term
protection against some cancers including breast, colon, and, prostate and if eaten as part
of a daily diet may even inhibit tumor growth (Nynca and Ciereszko, 2006). Another
animal study found that young rats injected with genistein and then exposed to cancer
causing agent later in life developed fewer mammary tumors and required more time to
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develop them than the non-exposed rats (Padilla-Banks, et al., 2006). Another study
reported that infants on soy infant formulas have improved cholesterol synthesis later in
life which support the idea that phytoestrogens are bioactive and can have effects in
humans at levels in soy formula.
As for adverse health effects, the most likely risk associated with phytoestrogens
deal with infertility and developmental problems. According to modern day analyses
many of the plants historically used for their ability to prevent pregnancy or cause
miscarriages contain phytoestrogens and other hormonally active substances (Hughes,
1988). Sheep grazing pastures with the phytoestrogen containing clover in Australia
suffered from reproductive problems and infertility (Dusza, et al., 2006). Summer time
grasses containing phytoestrogens were found to be responsible for reduced number of
offspring in the California quail (Wilhelms, et al., 2006).
Some scientists believe that plants make phytoestrogens as a defense mechanism
to stop overgrazing or limit predation by plant eating animals. Instead of protecting
themselves with thorns or other external defenses these plants that contain phytoestrogens
use chemicals that affect the predatory animal’s fertility (Farnsworth, et al., 1975). Thus
the predator’s population decreases and more plants can prosper.
This thesis examines the pre- and postnatal dietary influence of phytoestrogens on
the reproductive organs of male and female neonatal pigs as a model for human infants
on a soy based diet. The prenatal influence may promote or hinder the receptor
availability, which in turn has a bearing on the postnatal dietary influence to the neonate.
Our hypothesis is that the oral administration of phytoestrogen will cause an abnormal
increase in the reproductive tract of neonatal male and female pigs.
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CHAPTER II
LITERATURE REVIEW
The role of hormones
Estrogen
Estrogens are a group of steroid compounds named for their importance in the
estrous cycle and function as the primary female sex hormone. Estrogen influences the
growth, differentiation, and functioning of many target tissues (Pineda and Dooley,
2003). These include tissues of the female and male reproductive systems such as
mammary gland, uterus, vagina, ovary, testes, epididymis, and prostate (Kuiper, et al.,
1998). Like all steroid hormones, estrogens readily diffuse across the cell membrane
where they interact with estrogen receptors (Beato and Klug, 2000). The three major
naturally occurring estrogens in women are estradiol, estriol, and estrone which are all
produced from androgens through actions of enzymes (Cupps, 1991). From menarche
(time of first menstruation) to menopause the primary estrogen is 17β-estradiol. In
postmenopausal women more estrone is present than estradiol (Berne, et al., 2010).
A range of synthetic and natural substances has been identified that also possess
estrogenic activity. Synthetic substances of this kind are known as xenoestrogens while
plant products with estrogenic activity are called phytoestrogens, and those produced by
fungi are known as mycoestrogens (Burton and Wells, 2002). Unlike estrogens produced
by mammals, these substances are not necessarily steroids (Setchell, 1998).
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Estrogen is produced primarily by developing follicles in the ovaries, the corpus
luteum, and the placenta. Follicle-stimulating hormone (FSH) and luteinizing hormone
(Wilhelms, et al., 2006) stimulate the production of estrogen in the ovaries (Cupps,
1991). Some estrogens are also produced in smaller amounts by other tissues such as the
liver, adrenal glands, and the breasts. These secondary sources of estrogen are especially
important in postmenopausal women. Synthesis of estrogens starts in theca interna cells
in the ovary, by the synthesis of androstenedione from cholesterol (Pineda and Dooley,
2003). Androstenedione is a substance of moderate androgenic activity. This compound
crosses the basal membrane into the surrounding granulosa cells, where it is converted to
estrone or estradiol, either immediately or through testosterone. The conversion of
testosterone to estradiol, and of androstenedione to estrone, is catalyzed by the enzyme
aromatase (Carreau, et al., 2006).
Estrogens promote the development of female secondary sex characteristics, the
thickening of the endometrium, and other aspects of regulating the menstrual cycle
(Guyton and Hall, 2006). While estrogens are present in both men and women, they are
usually present at significantly higher levels in women of reproductive age. Furthermore,
there are several other structural changes induced by estrogen, such as decelerate height
growth, accelerate metabolism, reduce muscle mass, maintenance of vessel and skin,
reduce bone resorption, and increase bone formation (Berne, et al., 2010). Since estrogen
circulating in the blood can negatively feed-back to reduce circulating levels of FSH and
LH, most oral contraceptives contain a synthetic estrogen, along with a synthetic
progestin. Even in men, the major hormone involved in LH feedback is estradiol, not
testosterone.
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Estrogen and other hormones are given to postmenopausal women in order to aid
in the prevention of osteoporosis as well as treat the symptoms of menopause such as hot
flashes, vaginal dryness, urinary stress incontinence, chilly sensations, dizziness, fatigue,
irritability, and sweating (Guyton and Hall, 2006).
Role of estrogen in males
Both testosterone and estrogens have an enveloping role throughout the bodies of
both sexes (by either one, the other, or synergistically), which have been shown to play a
fundamental role in several major diseases, such as cardiovascular diseases, osteoporosis,
and reproductive organ cancers (Kuiper, et al., 1998).
In males, estrogen regulates certain functions of the reproductive system
important to the maturation of sperm and may be necessary for a healthy libido. The
established role of estrogen from the testis in males is known to cause negative-feed-back
on the production of FSH (Finkelstein, et al., 1991) and conversely aromatized estrogen
from the brain is responsible for defeminazation of the hypothalamus along with the
maintenance of sexual behavior in adulthood (Sharpe, 1998). The high level of estrogen
receptors on the efferent ducts is evidence that the hormone plays a role here (Goyal, et
al., 1997) along with a negative role in the regulation and differentiation of Leydig cell
development during puberty and testosterone production by differentiated adult Leydig
cells (Ge, et al., 1999). Estrogen receptor-α (ER-α) knockout mouse, human males with
inactivating mutations in the genes encoding aromatase or ER-α, and the discovery of a
second estrogen receptor (ER-β) has caused an increase in research on the effects of
estrogen on the male, from precoitum through adulthood, in an effort to obtain a better
understanding of the role estrogen plays in the male throughout life (Sharpe, 1998).
5

Adult boars produce androgens and high amounts of estrogen, the latter being in
excess of the amount known to occur in estrous females (Claus and Hoffmann, 1980;
Haeussler, et al., 2007), which occurs exclusively in the Leydig cells. Van Straaten and
Wensing (1978) reported three consecutive stages of Leydig cell development: a transient
development in the fetal period, a transient development in the perinatal period and a
final development from puberty onwards. These first stage cells, classified as fetal-type
Leydig cells (Abney, 1999), have a peak testosterone production around day 37
postcoitum (Haeussler, et al., 2007) which are necessary to stimulate Wolffian duct
development and promote sexual differentiation (Abney, 1999). The second transient
development occurs between 95 days postcoitum until about postnatal day 18 while the
final development is initiated about 13 weeks after farrowing (Van Straaten and Wensing,
1978).
Like other steroid hormones, testosterone is derived from cholesterol. The largest
amounts of testosterone are produced by the testes (Guyton and Hall, 2006). It is also
synthesized in far smaller quantities in women by the thecal cells of the ovaries, by the
placenta, as well as by the zona reticularis of the adrenal cortex in both sexes (Pineda and
Dooley, 2003). In the testes, testosterone is produced by the Leydig cells. The male
generative glands also contain Sertoli cells, which require testosterone for
spermatogenesis. Like most hormones, testosterone is supplied to target tissues in the
blood where much of it is transported bound to a specific plasma protein, sex hormone
binding globulin. Furthermore, there are two possible modifications on it, giving it
further ability (Berne, et al., 2010). In both men and women, testosterone plays a key
role in health and well-being as well as in sexual function. Examples include enhanced
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libido, increased energy, increased production of red blood cells and protection against
osteoporosis (Guyton and Hall, 2006).
Feedback control of hormone secretion
Feedback circuits are at the root of most control mechanisms in physiology, and
are particularly prominent in the endocrine system. Instances of positive feedback
certainly occur, but negative feedback is much more common. Negative feedback is seen
when the output of a pathway inhibits inputs to the pathway (Berne, et al., 2010).
Feedback loops are used extensively to regulate secretion of hormones in the
hypothalamic-pituitary axis. Gonadotrophin releasing hormone (GnRH) from the
hypothalamus is secreted into the pituitary gland where it stimulates FSH and LH
secretion by the gonadotrophs (Pineda and Dooley, 2003). In females, FSH stimulates
follicular development and estrogen secretion while LH causes ovulation. The excess
amounts of circulating ovarian hormones exert a negative feedback causing a decrease in
production of GnRH and consequently FSH and LH. In males, this same process is
performed except the target organ is the testis. The FSH stimulates sperm formation in
the seminiferous tubules and LH is responsible for testosterone secretion from the Leydig
cells. The excessive testosterone production inhibits FSH and LH by negative feedback.
Removal of the ovaries (surgery or menopause) or castration causes an increased
unregulated production of FSH and LH (Dukes and Reece, 2004).
Hormone receptors
Hormonal receptors are large proteins and need to be present for stimulation to
occur at the target tissue. Each cell of the tissue contains between 2,000 and 100,000
receptors to support a variety of hormones. Each receptor and hormone has a high
7

specificity that is similar to a lock and key (Mangelsdorf, et al., 1995). The number of
receptors on a given cell changes through the course of a day or even minute to minute.
The major mechanism of action of steroid hormones consists of specific steroid hormone
binding to its receptor, transformation of the bound receptor to the active form, and
binding of the steroid-receptor complex to DNA followed by gene activation (Grody, et
al., 1982; Murdoch and Gorski, 1991). An example of this scenario is the binding of a
hormone to its receptor thus causing a decrease in receptor availability either by
inactivation of some of the receptor molecules or because of decreased receptor
production. This down regulation of receptors decreases the responsiveness of the target
tissue to this hormone. Some hormones cause an up regulation of receptors, which
happen because the stimulating hormone induces the formation of more receptor
molecules than normal thus causing the target tissue to become more responsive to the
hormonal stimulus (Brann, et al., 1995; Beato and Klug, 2000). For instance, in the case
of estrogens, many compounds, which are known to be more active than the natural
hormone estradiol, bind very poorly to the estrogen receptor (Raynaud, et al., 1973). In
fact, one of the most active estrogens known, i.e. 11 fl-acetoxyestradiol, has less than 1%
of the binding to the estrogen receptor relative to estradiol (Korach, et al., 1987).
Conversely, certain compounds, which bind strongly to the estrogen receptor compared
to estradiol, have poor estrogenic activity (Korach, et al., 1989).
Maternal anatomy concerning fetal development
Fetal growth regulation has been identified using a range of techniques which
include but are not limited to hormone administration to the mother and fetus, gene
knockout, and disruptive physiological procedures (Fowden and Forhead, 2004).
8

Maternal nutrition (McPherson, et al., 2004) and hormones can play a major role in
control of fetal growth. Tissue accretion and differentiation requires tight coordination if
development is to proceed normally in utero.
Fowden and Forhead (2004) reported that hormones present in the fetal
circulation can be accounted for from four main sources. They may be secreted by the
endocrine glands of the fetus. The fetal pancreas, thyroid, pituitary and adrenal glands are
functional early in gestation and become progressively more responsive to stimuli later in
gestation. Hormones may be derived from the uteroplacental tissues, which produce a
number of hormones including steroids, peptides, glycoproteins, and eicosanoids that are
released into umbilical and uterine circulations. Lipophilic hormones such as steroids
and thyroid hormones may be derived from the mother by transplacental diffusion. The
amount of hormone transferred in this way depends on the materno-fetal concentration
gradient and the permeability of the placental barrier, both of which vary between
species.
Hormones in fetal plasma may be derived from circulating precursor molecules
by metabolism in the fetal or placental tissues (Fowden and Forhead, 2004). Because of
placental permeability which is termed ‘early-life programming’ (Seckl, 2004) the
severity of the insult, nutritional and hormonal (Seckl, 2004) may vary according to the
type, duration, severity, and gestational age (Fowden, et al., 2006). Haussmann and
coworkers (2000) reported that administration of exogenous adrenocorticotropic hormone
during gestation alters hypothalamic-pituitary-adrenal axis (HPA) of the sow’s
subsequent offspring offering evidence for prenatal programming.
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Female and male fetal anatomy development
Early life environmental factors influence prenatal development and may cause
structural and functional changes that remain persistent throughout life (Seckl, 2004).
Environmental challenges lead to altered cellular protein abundance, which includes
receptors, ion channels, transporters, enzymes, growth factors, cytoarchitectural proteins,
binding proteins, and components of several intracellular signaling pathways. These
changes can occur at any point in development but long term consequences are amplified
during late gestation and can affect the morphology and physiology of tissues and organs
as a whole (Fowden, et al., 2006). In many vertebrate species males show a burst of
androgen secretion near birth which permanently programs steroid metabolizing enzyme
expression in the liver while estrogens exert organizational effects on the developing
central nervous system both of which happen during the perinatal period with effects
persisting throughout life without any subsequent sex steroid manipulations (Seckl,
2004). The HPA axis is functional in utero and is known to affect fetal growth and
development of some fetal tissues and organ systems (Poore and Fowden, 2003).
Estrogen receptors
The dual role as agonist or antagonist of isoflavones may be in part due to the
receptor availability and selectivity for estrogen (Setchell and Cassidy, 1999). Just over a
decade ago Kuiper, et al. (1997) cloned a novel member of the nuclear receptor family,
named estrogen receptor β, to distinguish it from the classical estrogen receptor α subtype
(Setchell and Cassidy, 1999). The distribution and affinity of estrogen receptor-α (ER-α)
and estrogen receptor-β (ER-β) are different and this may help to explain the estrogenic
promotion or inhibition among the various tissues and organs of the body (Kuiper, et al.,
1997).
10

Two specific nuclear estrogen binding sites have been described in normal and
malignant tissues. Type I sites represent classical ERs with high affinity for estradiol in
relatively low quantities, while type II sites are present in greater quantities and have a
reduced affinity for estradiol (Markaverich, et al., 1981; Gray, et al., 1994). Estrogen
receptor α is expressed in major female organs such as ovary, uterus, vagina, mammary
gland, and certain areas of the central nervous system, most notably the hypothalamus
(Muramatsu and Inoue, 2000).
Predominant expression of rat ER-β mRNA, the newer of the two, can be found in
brain, bone, bladder, and vascular epithelia (Kuiper, et al., 1997). Studies have clearly
shown the physiological importance of ERβ in the function of rat ovary, its role during
testicular development, spermatogenesis in rats, and its role in human breast cancer
(Sasano, et al., 1999; van Pelt, et al., 1999). It has also been found that the relative molar
binding affinities of various estrogenic compounds reveal that phytoestrogens have
significantly higher affinities for ER-β over ER-α (Kuiper, et al., 1997; Setchell, 2001).
This suggest the new, ER-β may be responsible for the action of nonsteroidal estrogens
(Setchell and Cassidy, 1999). Ren et al. (2001) reported that ERβ gene expression is
down regulated in the neonatal hypothalamus of male piglets gestationally exposed to
daidzein through maternal diet. Maternal dietary intake of genistein had no effect on
gene expression of ERα or ERβ in the medial preoptic area of male or female rat pups on
postnatal day ten (Takagi, et al., 2005).
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Isoflavones
Phytoestrogens
Phytoestrogens are naturally occurring plant chemicals (Setchell and Cassidy,
1999) that function as estrogen agonist, antagonist, or selective estrogen receptor
modulators (Badger, et al., 2002) that are often found in trace amounts in food which are
structurally and functionally similar to 17β estradiol (Burton and Wells, 2002). A single
plant often contains more than one class of phytoestrogen. For example, the soy bean is
rich in isoflavones, whereas the soy sprout is a potent source of coumestrol. The classical
definition of phytoestrogens encompasses compounds that exert estrogenic effects on the
central nervous system, induce estrus, and stimulate growth of the genital tract of female
animals (Lieberman, 1996).
The biological potencies of phytoestrogens vary. The majority of these
compounds are nonsteroidal in structure and vastly less potent than the synthetic
estrogens (10-3 to 10-5), and they vary between species, routes of administration, and end
points used (Price and Fenwick, 1985). In humans, after consumption of plant lignans
and isoflavones, complex enzymatic metabolic conversions occur in the gastrointestinal
tract, resulting in the formation of heterocyclic phenols with a close similarity in structure
to estrogens (Setchell, et al., 1984). Absorbed phytoestrogen metabolites undergo
enterohepatic circulation and may be excreted in the bile (Axelson and Setchell, 1981)
deconjugated by intestinal flora, reabsorbed, reconjugated by the liver, and excreted in
the urine (Adlercreutz, et al., 1986). Lignans and isoflavones can be measured in urine,
plasma, feces, semen, bile, saliva, and breast milk (Adlercreutz, et al., 1995).
Concentrations of the different phytoestrogen metabolites vary widely between
individuals even when a controlled quantity of an isoflavone or lignan supplement is
12

administered. As dietary phytoestrogen metabolism is predominantly determined by the
gastrointestinal flora (Kelly, et al., 1995; Kirkman, et al., 1995). A comprehensive
review introduced over 300 plants that possessed estrogenic activity (Farnsworth, et al.,
1975; Farnsworth, et al., 1975). Isoflavones and coumestans have been identified as the
most common estrogenic compounds in these plants and have been given the name
phytoestrogens of which majority are polyphenolic (Dusza, et al., 2006) compounds that
have structural similarities to natural and synthetic estrogens and antiestrogens. The
biological potency of phytoestrogens vary and are less potent than those of the natural
hormone estradiol (Burton and Wells, 2002).
Phytoestrogens may exert biological activity by other mechanisms. For example,
the isoflavone genistein is a potent selective inhibitor of tyrosine kinase in both human
(Morrison, et al., 1996) and rat myometrial cells (Kusaka and Sperelakis, 1995). A
similar effect is also seen in human ovarian carcinoma cells (Bagnato, et al., 1997) and in
adenovirus infected cell lines (Daly and Reich, 1993). It is of note that daidzein, which
has a similar structure to genistein, has no effect on tyrosine kinase activity (Kusaka and
Sperelakis, 1995). In human leiomyosarcoma cells, both genistein and daidzein inhibit
fast sodium current by directly blocking fast sodium channels. The effects of
phytoestrogens can also vary depending on the species, sex, dose, exposure time in
laboratory animals, and route of administration (Murkies, et al., 1998).
Isoflavonoids comprise a large and very distinctive subclass of flavonoids.
Isoflavones constitute the largest group of natural isoflavonoids and some of the more
extensively researched compounds are genistein, daidzein, and glycitein of which
genistein is present in the greatest quantities in a naturally occurring plant (Ford, et al.,
2006). The isoflavones displaying estrogenic activity occur almost exclusively in
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legumes and beans (Price and Fenwick, 1985; Knight and Eden, 1995) and in products
that contain most or all of the bean (Dwyer, et al., 1994; Messina, et al., 1994). Second
generation soy foods are made by adding soy ingredients to a wide variety of
manufactured foods, hence the isoflavone content is diminished. The scientific interest in
these natural compounds was initiated by their potential hormonal action in grazing
animals that was first observed in relation to a syndrome known as clover disease in
sheep in Western Australia in the mid-1940’s (Dusza, et al., 2006).
Isoflavones in plants occur predominately as glycosides (Setchell, 2001) in which
their availability is affected by cultivation and local conditions such as temperature,
rainfall, soil fertility, pest, and disease damage (Dusza, et al., 2006). In order for a
chemical to possess any physiological activity it must reach a target as a chemical that
has the capability of triggering the same response as the natural hormone itself
(Lieberman, 1996). After analysis of several soy foods for the content of the highly polar
(water soluble) compound isoflavone it was found that most contained 1.2-4.2 mg/g of
dry weight (Dusza, et al., 2006). With the increased amount of soy supplements there are
concerns regarding the potentially adverse effects that could be presented from
megadosing, a factor all too common in the supplement area today (Setchell and Cassidy,
1999).
Genistein
An isoflavone found at high concentrations in soy-based products (Dusza, et al.,
2006) genistein exhibits in vitro and in vivo estrogenic activity. It has also been reported
to display tyrosine kinase inhibitory properties without affecting serine and threonine
protein specific kinases (Akiyama, et al., 1987). Reports of the beneficial and
14

detrimental effects of genistein are abundant and highly controversial (Jefferson, et al.,
2007). Some of the beneficial effects are reduction of mammary cancer in rats and lower
cholesterol levels in humans (Henley and Korach, 2006). The detrimental effects consist
of diminished reproductive capacity in animals, induced uterine adenocarcinomas in a
neonatal mouse, and an increase in the incidence of mammary tumors in rats (Jefferson,
et al., 2007).
Isoflavones such as genistein can be conjugated to glucose or other carbohydrate
moieties. Carbohydrate conjugates are called glycosides and glucose conjugates are
called glucosides and the genistein glucoside is called genistein. In unfermented soy
products small amounts of genistein are present as aglycones, the unconjugated form,
however most will be conjugated to a sugar molecule to form glycosides. Conjugation
with glucose groups increases water solubility of genistein, however glucoside
compounds are deconjugated by gut microflora to form the active aglycone under acidic
conditions or by metabolic enzymes. The aglycone is reconjugated in the gut wall and
can enter the portal circulation (Setchell, 1998).
Genistein has been the phytoestrogen of greatest interest at present and has been
shown to exert both proliferative and antiproliferative effects in human cell lines (Wang,
et al., 1996). In the human estrogen receptor (ER)-positive MCF-7 breast cancer cell line,
these effects are biphasic and concentration dependent, with stimulation of cell growth
occurring at low concentrations of genistein [10-5–10-8 M] and inhibition at higher
concentrations [10-4–10-5 M]. At low concentrations genistein competes with estradiol
for binding to the ER with a 50% inhibition concentration of 5 x 10-7 m and stimulates
the expression of pS2 mRNA, a specific marker of ER-mediated estrogen like activity
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(Wang, et al., 1996). Other studies have shown a similar stimulatory effect with
daidzein, equol, and enterolactone at 10-6 M concentrations (Sathyamoorthy, et al., 1994).
One study concluded that genistein inhibits epidermal growth factor receptor
(EGF-R) tyrosine auto phosphorylation (Akiyama, et al., 1987), whereas another was
unable to demonstrate this effect and concluded that the isoflavones exert their inhibitory
effects either downstream from EGF-R tyrosine auto phosphorylation or by some other
mechanism (Peterson and Barnes, 1996).
Current research is focused on the levels of exposure of infants to isoflavones
through their diets. Adults have an isoflavone intake of approximately 1 mg/kg/d
compared to infants who ingest 6-9 mg/kg/d (Padilla-Banks, et al., 2006). This is 6-11
times higher than the amount reported to have hormonal effects that alter the menstrual
cycle in adult women (Cassidy, et al., 1994).
Genistein, a weak estrogen (Ford, et al., 2006), causes ordinary uterotropic
responses such as increases in uterine wet weight, epithelial cell height, gland number,
and lactoferrin expression. Receptor binding assays showed genistein had a stronger
affinity for ER-β in comparison to ER-α by 20-30 fold in the mouse model (Kuiper, et al.,
1998). However, during in vitro studies the binding affinity for the two receptors was
more in unison. Henley and Korach (2006) state that this may elicit effects in vivo
through both estrogen receptors (ER)-α and ER-β mediated pathways. In a study
performed by Henley and Korach (2006) to determine the role of ER-α in the uterine
response to genistein two groups of mice were used. Ovariectomized wild type (WT) and
estrogen receptor α knock out (ERαKO) mice were treated with corn oil, estradiol (10
µg/kg/d), or genistein (50 µg/kg/d) for three days and uterine wet weights were
determined. Both genistein and estradiol treatments increased wet weights in WT mice,
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whereas neither substance increased wet weights in the ERαKO. This provided evidence
that ER-α is needed for genistein induced uterotropic effects.
A similar experiment was performed to determine whether genistein was
signaling in the ovary through ER-α, ER-β, or a non-receptor mediated mechanism.
Treatment with genistein increased the incidence of multioocyte follicles in WT and
ERαKO mice in a dose dependent manner. The ERβKO mice had a significant decrease
in the incidence of multioocyte follicles suggesting that ER-β is required for genistein to
elicit any effects. However conflicting data make it difficult to correlate animal models
with human exposure (Henley and Korach, 2006)
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CHAPTER III
MATERIALS AND METHODS
Sows and feed
In this study eight Yorkshire/Landrace crossbred sows were purchased from
Prestage Farms (West Point, MS), in the spring and again in the fall for a replicate trial, at
the Metabolism Research Facility, South Farm, at Mississippi State University
(Starkville, MS). Sows at 100 days gestation were randomly assigned to one of the two
treatment groups and placed in farrowing crates the day of arrival with control sows
(CON; n = 8) having a mean body weight (BW) of 275.8 ± 7 kg and experimental sows
(T; n = 8) having a mean body weight of 278.8 ± 13 kg respectively. Sows (CON and T)
were fed 2 kg of a lactating sow diet (prepared by Mattox Feed Mill, Aberdeen, MS) that
consisted of a mixture of ground corn (64.75%), soybean meal (29.25%) and Sow 120
premix (6%) per day. From the day of arrival, treated sows received a total of 1.5 mg/kg
body weight of isoflavone (Novasoy 70% isoflavone extract, Archer Daniels Midland
Co., Decatur, IL) per day (added to the ration at am and pm feedings) until farrowing at
which time the treatments were discontinued.
Neonatal pig treatments
Following farrowing, body weights of neonatal pigs (NP) (both male and female)
were recorded at farrowing and again on post natal day (PND) six with the latter being
used to randomly assign the NP to one of four treatments (n = 18 to 20/gender/treatment):
1) control (vehicle), 2) estradiol (50 µg/kg BW/d) as positive control, 3) low genistein
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dose (3 mg/kg BW/d) and 4) high genistein dose (9 mg/kg BW/d) within each of the two
sow treatments yielding eight NP treatments total. Neonates were weighed each morning
and treatments were adjusted according to body weight. Treatments were administered
orally (mimic route of exposure in infants) twice a day (half the dose in the morning, half
in the evening) for 7 days commencing on PND 7. All treatments were administered as a
suspension in Re-Sorb an oral hydration electrolyte product distributed by Pfizer Animal
Health.
Tissue collection
On PND 14 neonates were sedated with a mixture of Xylazine (2.2 mg/kg BW)
and Ketamine (2.2 mg/kg BW). After lateral recumbency NPs were euthanized with
Beuthanasia D (2.2 mg/kg BW) for tissue collection. The pituitary was recovered from all
neonates while ovaries, uterus, and cervix were collected from each female. Male tissue
collection consisted of testes, epididymi, and seminal vesicles. Neonatal pigs (male and
female) were decapitated for expeditious removal of tissue specimens. The cranial cap
was removed and the pituitary excised. For female tissue collection two incisions were
made on the ventral side of the animal with the pubic symphysis being split in order to
gain access to the reproductive tract. After removal of the intact reproductive tract,
excess fascia was trimmed, the vaginal tract segregated just proximal to the urethral
process, and the entire reproductive tract weighed. After initial weighing; the cervix,
uterus, and ovaries were separated and weighed individually. After initial weighing the
cervix was transected longitudinally, the uterus bisected, and one of the ovaries was
placed in separate containers of 10% formalin solution. Each ipsilateral female tissue
section was snap frozen in liquid nitrogen. For male tissue collection, each testis and
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epididymis were removed together, excess fascia trimmed, and weighed intact. After
initial weighing, each testis and epididymis were separated and weighed individually.
After weights were collected a testis and epididymis were placed in separate containers of
10% formalin solution. Each ipsilateral male tissue was snap frozen in liquid nitrogen.
Both male and female snap frozen tissues were stored at -80 oC until retrieved for
histological, immunohistochemical, (proliferative cell nuclear antigen assay as a measure
of tissue proliferation) and molecular (apoptotic, estrogen receptor α and β, and
proteomic) analyses, respectively.
Histological preparation
For histological analysis, the uterine samples were cross sectioned and cervical
samples were collected from both the uterine and vaginal regions of the cervix while the
entire ovary was used for histological analysis. The testicle and epididymis were cross
sectioned perpendicular to the long axis.
Samples were initially fixed in 10% buffered formalin solution then transferred to
a Tissue-Tek Vacuum Infiltration Processor Model E150 (Sankura Fintek USA. Inc
Torrence, CA) for approximately 13 hours. Processing of tissue samples once in the
machine consist of 10% neutral buffered formalin solution for two hours, 70% alcohol for
one hour, 95% alcohol for two hours, 100% alcohol for two hours, 50/50 alcohol/xylene
solution for one hour, xylene for two hours, and paraffin for four hours. Embedded
paraffin tissue blocks were then cut in 5µm thick sections, placed on slides an allowed to
dry in an oven. Tissues were then de-paraffinized and then stained with hematoxylin and
eosin for morphometric analysis.
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Statistical Analysis
The trials were performed at different times of the year, the first in the spring and
the second in the fall. Analysis was performed for differences in time and there were no
differences between trials. The data were combined from both trials and is presented in
the results section. The experiment was analyzed as a split plot design with sow
treatment and pig treatment being the main effects and an interaction of sow treatment
and pig treatment. Error was tested as sow treatment nested in sow. Statistical analyses
were performed using GLM procedures of S.A.S. v9.1.3 (SAS Institute, Cary, NC) and
least square means (LSM ± SEM) were calculated for the three analyses. Data with a P
value less than 0.05 were considered significant and data with a P value less than 0.1
were considered as trends.
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CHAPTER IV
RESULTS
Trial 1
Body weights did not significantly differ among treatment groups on PND 14
tissue collection in neonatal pigs as shown in Table 4.1, 4.2, and 4.3. Total pituitary
weights (wet tissue weights or expressed as a percentage of body weight) did not
significantly differ with respect to neonatal pig treatments. However, there was a
tendency for pituitary wet tissue weights as a percentage of body weight (P = 0.079) from
female neonatal pigs as shown in Figure A.1 to be heavier in Novasoy treated sows and
estradiol treated neonatal pigs. Analysis of ovary weight, separately (right or left) or
paired, was not significantly different for wet tissue weight or as a percent of body weight
regardless of sow or neonatal pig treatment. Uterus as a percent of body weight and wet
tissue weights was significantly increased (P < 0.05) over control and both levels of
genistein in the estradiol treated neonatal pigs as shown in Figure A.2 and A.3. Cervix
actual weight was significantly increased (P < 0.05) in estradiol treated neonatal pigs as
shown in Figure A.4. Figure A.5 shows a significant interaction (P < 0.05) for the cervix
as a percent of body weight with Novasoy treated sows and estradiol treated neonatal pigs
being heavier than control sows and estradiol treated neonatal pigs along with both being
different than the other six treatment combinations. The reproductive tract wet tissue
weights and as a percent of body weight was significantly (P < 0.05) increased in
estradiol treated female neonatal pigs over control and both levels of genistein treatment
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as shown in Figures A.6 and A.7. In male neonatal pigs the seminal vesicle as a percent
of body weight had a tendency (P = 0.0558) to be increased for low genistein over
control, high genistein, and estradiol as shown in Figure A.8. Right and left testicle wet
tissue weight and as a percent of body weight was significantly different (P < 0.05) with
respect to Novasoy treated sows as shown in Figures A.9, A.10, A.11, andA.12
respectively. Epididymal wet tissue weight and as a percent of body weight was not
significantly different with respect to sow or neonatal pig treatment. However when
testicle and epididymal weights were combined, the right testicle and epididymis wet
tissue weight and as a percent of body weight was significantly different (P < 0.05) with
respect to Novasoy treated sows as shown if Figures A.13 and A.14. Figure A.15 shows
the left testicle and epididymis wet tissue weight combined had a tendency to be heavier
in Novasoy treated sows. When analyzed as a percent of body weight in Figure A.16
there was a significant difference (P < 0.05) with respect to Novasoy treated sows.
Additional data, from Trial 1, with respect to statistical analysis, can be found in Tables
A.1 through A.6 in the Appendix.
Table 4.1

Effects of sow treatment on neonatal body weights
Female Body Weights (kg)

Control(n=4)
Novasoy(n=4)

Male Body Weights (kg)

4.4 ± 0.2(n=21)

4.3 ± 0.2(n=24)

4.9 ± 0.2(n=20)

4.1 ± 0.2(n=25)

0.6742
0.8827
P value
Note: Effects of isoflavone (Novasoy 70) supplementation of sow diets starting at 100
days of gestation on body weight of female and male neonatal pigs. Data presented as
least square means (LSM) ± standard error (SE).
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Table 4.2

Effects of neonatal pig treatment on neonatal body weights
Female Body Weights (kg)

Control
Low Genistein
High Genistein
Estradiol

Male Body Weights (kg)

4.9 ± 0.3(n=10)

4.2 ± 0.3(n=12)

4.7 ± 0.3(n=10)

4.2 ± 0.2(n=13)

4.6 ± 0.3(n=11)

4.2 ± 0.2(n=13)

4.5 ± 0.3(n=10)

4.2 ± 0.3(n=11)

0.7823
0.8925
P value
Note: Effect of 7 days of in vivo exposure with estrogenic compounds on body weights of
female and male neonatal pigs. Data presented as LSM ± SE
Table 4.3

Effects of sow and neonatal pig treatment on neonatal body weights

Control(n=4)

Novasoy(n=4)

Control
Low Genistein
High Genistein
Estradiol
Control
Low Genistein
High Genistein
Estradiol

Female Body
Weights (kg)

Male Body
Weights (kg)

4.8 ± 0.4(n=5)

4.2 ± 0.4(n=6)

4.5 ± 0.4(n=5)

4.5 ± 0.4(n=6)

4.1 ± 0.4(n=6)

4.4 ± 0.4(n=6)

4.4 ± 0.4(n=5)

4 ± 0.4(n=6)

5 ± 0.5(n=5)

4.1 ± 0.4(n=6)

4.9 ± 0.5(n=5)

3.9 ± 0.3(n=7)

5.1 ± 0.4(n=5)

3.9 ± 0.3(n=7)

4.7 ± 0.4(n=5)

4.3 ± 0.4(n=5)

0.9974
0.7299
Note: Effects of isoflavone (Novasoy 70) supplementation of sow diets starting at 100
days of gestation and 7 days of in vivo exposure with estrogenic compounds on body
weights of female and male neonatal pigs. Data presented as LSM ± SE.
P value

Trial 2
Body weights did not significantly differ among treatment groups on PND 14
tissue collection in neonatal pigs as shown in Table 4.4, 4.5, and 4.6. Total pituitary
weights (wet tissue weights or expressed as a percentage of body weight) did not
significantly differ with respect to sow treatment or neonatal pig treatment. When
ovaries were analyzed separately (right or left ovary) there was a significant difference
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with the right ovary wet tissue weight (P < 0.05) and as a percentage of body weight (P <
0.05), however only the left ovary tissue weight as a percentage of body weight was
significantly different (P < 0.05). Right ovary wet tissue weights with respect to estradiol
treatment were heavier than control as shown in Figure A.17. Right ovary as a percentage
of body weight was heaviest in estradiol treated neonatal pigs which differed from both
levels of genistein that were heavier than control pigs as shown in Figure A.18. Left
ovary as a percentage of body weight was heavier in estradiol treated neonatal pigs as
shown in Figure A.19. Paired ovarian wet tissue weights had a tendency (P = 0.0558) for
estradiol treated neonatal pigs to be heavier than control and both levels of genistein as
shown in Figure A.20. Paired ovarian weight as a percentage of body weight was
heaviest in estradiol treated neonatal pigs which differed from both levels of genistein
that were heavier than control pigs as shown in Figure A.21. Estradiol treated neonatal
pig uterus as a percent of body weight and wet tissue weights was significantly increased
(P < 0.05) over control and both levels of genistein as shown in Figure A.22 and A.23.
Cervix actual weight and as a percent of body weight was significantly increased (P <
0.05) in estradiol treated neonatal pigs as shown in Figure A.24 and A.25. The
reproductive tract wet tissue weights and as a percent of body weight was significantly (P
< 0.05) increased in estradiol treated female neonatal pigs over control and both levels of
genistein treatment as shown below in Figures A.26 and A.27. In male neonatal pigs the
pituitary wet tissue weight from Novasoy treated sows were significantly (P < 0.05)
heavier than control sows as shown in Figure A.28. Additional data, from Trial 2, with
respect to statistical analysis, can be found in Tables A.7 through A.12 in the Appendix.
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Table 4.4

Effects of sow treatment on neonatal body weights

Control(n=4)
Novasoy(n=4)

Female Body
Weight (kg)

Male Body
Weight (kg)

4.4 ± 0.2(n=17)

4.4 ± 0.3(n=15)

4.9 ± 0.2(n=17)

4.8 ± 0.3(n=22)

0.3712
0.2622
P value
Note: Effects of isoflavone (Novasoy 70) supplementation of sow diets starting at 100
days of gestation on body weight of female and male neonatal pigs. Data presented as
LSM ± SE.
Table 4.5

Effects of neonatal pig treatment on neonatal body weights

Control
Low Genistein
High Genistein
Estradiol

Female Body
Weight (kg)

Male Body
Weight (kg)

4.9 ± 0.3(n=7)

4.6 ± 0.5(n=8)

4.7 ± 0.3(n=10)

4.4 ± 0.4(n=10)

4.5 ± 0.3(n=9)

4.6 ± 0.4(n=10)

4.5 ± 0.3(n=8)

4.7 ± 0.4(n=9)

0.8523
0.9718
P value
Note: Effect of 7 days of in vivo exposure with estrogenic compounds on body weights of
female and male neonatal pigs. Data presented as LSM ± SE.
Table 4.6

Effects of sow and neonatal pig treatment on neonatal body weights

Control(n=4)

Novasoy(n=4)

Female Body Weights
(kg)

Male Body Weights
(kg)

4.7 ± 0.4(n=4)

4.6 ± 0.7(n=3)

4.5 ± 0.4(n=5)

3.9 ± 0.7(n=4)

4 ± 0.4(n=4)

4.3 ± 0.6(n=4)

4.3 ± 0.4(n=4)

4.8 ± 0.6(n=4)

5 ± 0.5(n=3)

4.7 ± 0.5(n=5)

4.9 ± 0.5(n=5)

5 ± 0.5(n=6)

5.1 ± 0.4(n=5)

5 ± 0.5(n=6)

4.7 ± 0.4(n=4)

4.5 ± 0.6(n=5)

Control
Low Genistein
High Genistein
Estradiol
Control
Low Genistein
High Genistein
Estradiol

0.7725
0.6542
Note: Effects of isoflavone (Novasoy 70) supplementation of sow diets starting at 100
days of gestation and 7 days of in vivo exposure with estrogenic compounds on body
weights of female and male neonatal pigs. Data presented as LSM ± SE.
P value
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Combined Data from Trial 1 and Trial 2
With no differences between trial 1 and trial 2 in regards to time the data was
combined. Body weights did not significantly differ among treatment groups on PND 14
in neonatal pigs as shown in Table 4.7, 4.8, and 4.9. Total pituitary weights (wet tissue
weights or expressed as a percentage of body weight) did not significantly differ with
respect to neonatal pig treatments. However, there was a tendency for pituitary wet tissue
weights (P = 0.0842) and as a percentage of body weight (P = 0.0667) from female
neonatal pigs as shown in Figure 4.1 and 4.2 respectively to be heavier in Novasoy
treated sows compared to control sows. Paired ovarian wet tissue weights were not
significantly different regardless of treatment. When ovaries were analyzed separately
(right or left ovary) there was not a significant difference in left ovary wet tissue weight
or as a percentage of body weight, but the right ovary wet tissue weights were
significantly different. Right ovary weights with respect to estradiol treatment were
heavier (P < 0.05) than control and both levels of genistein for neonatal pig treatments
and there was a tendency (P = 0.0595) for right ovary wet tissue weights from neonatal
pigs to be heavier in Novasoy treated sows in comparison to control sows as detailed in
Figure 4.3 and 4.4 respectively. Uterus as a percent of body weight and wet tissue
weights was significantly increased (P < 0.05) over control and both levels of genistein in
the estradiol treated neonatal pigs as shown in Figure 4.5 and 4.6. Uterus as a percent
body weight as seen in Figure 4.7 also had a tendency (P = 0.0729) to be heavier in
Novasoy treated sows compared to control sows. Cervix actual weight and as a percent
of body weight were significantly increased (P < 0.05) in estradiol treated neonatal pigs
as shown in Figure 4.8 and 4.9. The intact reproductive tract wet tissue weights and as a
percent of body weight was significantly (P < 0.05) increased in estradiol treated female
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neonatal pigs over control and both levels of genistein treatment as shown below in
Figures 4.10 and 4.11. In male neonatal pigs the seminal vesicle as a percent of body
weight had a tendency (P = 0.0753) to be increased for low genistein over control, high
genistein, and estradiol as shown in Figure 4.12.
Table 4.7

Effects of sow treatment on neonatal body weights

Control(n=8)
Novasoy(n=8)

Female Body
Weights (kg)
4.4 ± 0.1(n=38)
4.3 ± 0.1(n=42)

Male Body
Weights (kg)
4.3 ± 0.2(n=39)
4.4 ± 0.1(n=47)

P value
0.6802
0.7583
Note: Effects of isoflavone (Novasoy 70) supplementation of sow diets starting at 100
days of gestation on body weight of female and male neonatal pigs. Data presented as
LSM ± SE.
Table 4.8

Effects of neonatal pig treatment on neonatal body weights
Female Body
Weights (kg)
4.4 ± 0.2(n=17)
4.4 ± 0.2(n=20)
4.3 ± 0.2(n=20)
4.4 ± 0.2(n=18)

Male Body
Weights (kg)
4.4 ± 0.2(n=20)
4.4 ± 0.2(n=23)
4.4 ± 0.2(n=23)
4.4 ± 0.2(n=20)

Control
Low Genistein
High Genistein
Estradiol
P value
0.9803
0.999
Note: Effect of 7 days of in vivo exposure with estrogenic compounds on body weights
of female and male neonatal pigs. Data presented as LSM ± SE.

28

Table 4.9

Effects of sow and neonatal pig treatment on neonatal body weights

Control(n=8)

Novasoy(n=8)

Control
Low Genistein
High Genistein
Estradiol
Control
Low Genistein
High Genistein
Estradiol

Female Body
Weights (kg)
4.4 ± 0.3(n=9)
4.3 ± 0.3(n=10)
4.4 ± 0.3(n=10)
4.7 ± 0.3(n=9)
4.4 ± 0.3(n=8)
4.6 ± 0.3(n=10)
4.2 ± 0.3(n=10)
4.1 ± 0.3(n=9)

Male Body
Weights (kg)
4.4 ± 0.3(n=9)
4.3 ± 0.3(n=10)
4.4 ± 0.3(n=10)
4.4 ± 0.3(n=10)
4.4 ± 0.3(n=11)
4.4 ± 0.3(n=13)
4.4 ± 0.3(n=13)
4.4 ± 0.3(n=10)

P value
0.393
0.9958
Note: Effects of isoflavone (Novasoy 70) supplementation of sow diets starting at 100
days of gestation and 7 days of in vivo exposure with estrogenic compounds on body
weights of female and male neonatal pigs. Data presented as LSM ± SE.
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Figure 4.1

Effects of sow treatment on neonatal pituitary weight.

Note: Effect of isoflavone (Novasoy 70) supplementation of sow diets starting at 100
days of gestation on wet weight of the pituitary gland recovered from female neonatal
pigs on post natal day 14. Data presented as LSM ± SE
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Figure 4.2

Effects of sow treatment on pituitary as a percent of body weight.

Note: Effect of isoflavone (Novasoy 70) supplementation of sow diets starting at 100
days of gestation on wet weight as a percent of body weight of the pituitary gland
recovered from neonatal pigs on post natal day 14. Data presented as LSM ±SE.
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Figure 4.3

Effects of neonatal pig treatment on right ovary weight.

Note: Effects of 7 days of in vivo exposure with estrogenic compounds on right ovary
tissue weights recovered from neonatal pigs. Genistein was administered orally at 3
mg/kg or 9 mg/kg and estradiol at 50 µg/kg body weight/day. Data presented as LSM
±SE.
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Figure 4.4

Effects of sow treatment on right ovary weight.

Note: Effect of isoflavone (Novasoy 70) supplementation of sow diets starting at 100
days of gestation on wet weight of the right ovary recovered from neonatal pigs on post
natal day 14. Data presented as LSM ±SE.
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Figure 4.5

Effects of neonatal pig treatment on uterus as a percent of body weight.

Note: Effects of 7 days of in vivo exposure with estrogenic compounds on uterus tissue
weights as a percent of body weight recovered from neonatal pigs. Genistein was
administered orally at 3 mg/kg or 9 mg/kg and estradiol at 50 µg/kg body weight/day.
Data presented as LSM ±SE.
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Figure 4.6

Effects of neonatal pig treatment on uterus weight.

Note: Effects of 7 days of in vivo exposure with estrogenic compounds on uterus tissue
weights recovered from neonatal pigs. Genistein was administered orally at 3 mg/kg or 9
mg/kg and estradiol at 50 µg/kg body weight/day. Data presented as LSM ±SE.

35

Figure 4.7

Effects of sow treatment on uterus as a percent of body weight.

Note: Effect of isoflavone (Novasoy 70) supplementation of sow diets starting at 100
days of gestation on wet weight of the as a percent of body weight recovered from
neonatal pigs on post natal day 14. Data presented as LSM ±SE.
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Figure 4.8

Effects of neonatal pig treatment on cervix weight.

Note: Effects of 7 days of in vivo exposure with estrogenic compounds on cervix tissue
weights recovered from neonatal pigs. Genistein was administered orally at 3 mg/kg or 9
mg/kg and estradiol at 50 µg/kg body weight/day. Data presented as LSM ±SE.
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Figure 4.9

Effects of neonatal treatment on cervix as a percent of body weight.

Note: Effects of 7 days of in vivo exposure with estrogenic compounds on cervix tissue
weights as a percent of body weight recovered from neonatal pigs. Genistein was
administered orally at 3 mg/kg or 9 mg/kg and estradiol at 50 µg/kg body weight/day.
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Figure 4.10

Effects of neonatal pig treatment on reproductive tract weight.

Note: Effects of 7 days of in vivo exposure with estrogenic compounds on reproductive
tract tissue weights recovered from neonatal pigs. Genistein was administered orally at 3
mg/kg or 9 mg/kg and estradiol at 50 µg/kg body weight/day. Data presented as LSM
±SE.
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Figure 4.11

Effects of neonatal pig treatment on reproductive tract weight as a percent
of body weight.

Note: Effects of 7 days of in vivo exposure with estrogenic compounds on reproductive
tract tissue weights as a percent of body weight recovered from neonatal pigs. Genistein
was administered orally at 3 mg/kg or 9 mg/kg and estradiol at 50 µg/kg body
weight/day. Data presented as LSM ±SE.
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Figure 4.12

Effects of neonatal pig treatment on seminal vesicle as a percent of body
weight.

Note: Effects of 7 days of in vivo exposure with estrogenic compounds on seminal
vesicle tissue weights as a percent of body weight recovered from neonatal pigs.
Genistein was administered orally at 3 mg/kg or 9 mg/kg and estradiol at 50 µg/kg body
weight/day. Data presented as LSM ±SE.
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CHAPTER V
DISCUSSION
Most studies show the relation between the chemical structure of phytoestrogens
and their estrogen-like activities. Results of studies conducted on laboratory animals as
well as on large farm animals have shown that the effects of phytoestrogens vary
depending on species, sex, routes of administration, dose, and exposure time. The effects
of individual phytoestrogens can vary considerably, being both species- and tissuedependent. There is a growing body of evidence that these plant-derived substances may
alter synthesis, secretion, and metabolism of hormones involved in the regulation of
reproductive processes. Such inconsistency may likely be explained by differences in
length of the experiment, form of the applied soy product, type of isoflavone and its
concentration in the diet. In addition, direction and degree of genistein or daidzein in
vivo effects appear to be dependent on species, reproductive status of a subject, individual
phytoestrogen metabolism, and even a blood sampling schedule.
Altered growth in utero is associated with a failure to thrive after birth in
domestic animals and an increased risk of cardiovascular disease in later life in humans
(Fowden, 1995). The factors affecting tissue accretion and differentiation in utero have
an important role in determining the subsequent health and life expectancy of the animal.
Lay et al. (Lay, et al., 1997) reported that transportation stress during gestation resulted
in enlarged pituitary glands in fetal calves. This stress induced alteration of the
hypothalamic-pituitary-adrenal axis was reported to be maintained for 150 days in calves
42

(Lay, et al., 1997). In our study, the tendency for pituitary wet tissue weights (P =
0.0842), pituitary as a percentage of body weight (P = 0.0667), uterus as a percentage of
body weight (P =0.0729), and right ovary wet tissue weight from female neonatal pigs to
be heavier in Novasoy treated sows in comparison to control sows signifies an in utero
effect. Rehfeldt, et al., (2001) reported that the neonatal pig intestinal tract and spleen
tissue weights to be heavier in porcine somatotropin treated gilts as compared to control
gilts. However after percentage of body weight was factored in there was only a
tendency for the intestinal tract to be heavier in porcine treated gilts. The treatment
window of porcine somatotropin in Rehfeldt’s study was days 10 to 27 which covered the
time of implantation and early development as opposed to our phytoestrogen treated sows
which were day 100 of gestation until farrowing. Fowden, et al.,(2006) noted that
although the sequence of developmental changes is similar across mammalian species
there is still some variance in the precise timing between animals. In rats, rabbits, and
rodents there is still some development after birth in contrast to pigs and sheep that are
physiologically mature at birth.
Reports indicate that altered growth in utero may be associated with reproductive
disorders later in life such as reduced uterus and ovary size (Ibanez, et al., 2000) as well
as menopause at an earlier age (Cresswell, et al., 1997). Estrogen receptors (ER) and
estradiol producing enzymes that enhance estrogen bioactivity are present in the human
ovary during fetal development. In a study performed on human fetuses both ERs were
localized in the granulose cells and also in the oocytes with the highest expression being
observed in fetal tissue collected from the last trimester (Vaskivuo, et al., 2005). (Da
Silva-Buttkus, et al., 2003) reported that although absolute ovarian mass was lower in
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runt piglets compared with their normally growing littermates, relative ovary mass
expressed in terms of body weight was not different between the two groups of piglets.
In our study, we mimicked the route of exposure seen in human infants, from
maternal exposure of phytoestrogens to fetal ingestion of phytoestrogens, as would be
seen through soy infant formula. The body weights as mentioned earlier were not
statistically different for sow treatment, pig treatment, or interaction of sow by pig
treatment analysis. Estradiol was used as a positive control to signify the ability of
intestinal absorption by male and female neonatal pigs. The absorption of genistein (3
mg/kg or 9 mg/kg BW) was not different than the control in all female tissues collected.
However, the tendency in male neonatal pigs for the seminal vesicle as a percent of body
weight to be heavier with a low dose of genistein (3 mg/kg BW) than the control, high
dose, and estradiol signifies the potential ability of genistein to be absorbed from the
intestinal tract and have an effect on the target tissue.
In a series of randomized crossover studies Setchell (2000) examined the
pharmacokinetics of daidzein and genistein in human adults fed different amounts and
types of soy foods and observed that elimination half life was different based on the
consistency of the food; elimination of liquid food was faster than solid food.
Phytoestrogen intake throughout the day will cause a higher plasma and urine
concentration (Setchell, et al., 1984), which would explain the low incidence rate of
hormone dependent diseases in Eastern countries unlike The United States.
Conclusion
Data from our study shows that oral administration of estrogen can cause an
increase in wet tissue weight alone and after being corrected for body weight. However,
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the two levels of genistein didn’t cause any of the tissues we collected to have any
abnormal increase in wet tissue weight or in tissue weight corrected for body weight.
The tendency for male seminal vesicle tissue to be heavier for low genistein
administration in the neonatal pig treatment could be attributed to different individual
collection parameters such as the amount of fascia trimmed after harvesting the tissue.
Future studies are ongoing analyzing the tissues for estrogen receptor expression
and histological analysis of tissue slides. These studies depending on outcome can be
used to depict further investigations. The sows treated with Novasoy were to mimic
vegetarian mothers that would be giving birth to neonates consuming soy formula as
infants. With the data combined from both trials the synergistic effect for the cervix and
pituitary of treated sows and treated neonatal pigs was found to be not statistically
significant. This would direct future research to be undertaken in a two step process.
One trial consisting of the sows being treated with Novasoy and the neonatal tissues
collected at birth could help explain the differences seen after combining the data from
both trials. The second trial would consist of collection of tissues from neonatal pigs at
different time intervals to analyze the long term effects of the consumption of
phytoestrogens. Urinalysis being added to the data collection would help substantiate the
byproducts of phytoestrogen consumption. Our research answered a few questions but the
results have caused so many more to be asked.
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APPENDIX A
SUPPLEMENTARY FIGURES AND TABLES FOR TRIAL 1 AND TRIAL 2
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Abbreviations
Reproductive Tract in grams (RTg)
Reproductive Tract as a percent of body weight (RT%)
Left Ovary in grams (LOg)
Left Ovary as a percent of body weight (LO%)
Right and Left Ovary in grams (RLOg)
Right and Left Ovary as a percent of body weight (RLO%)
Right Ovary in grams (ROg)
Right Ovary as a percent of body weight (RO%)
Uterus in grams (Ug)
Uterus as a percent of body weight (U%)
Cervix in grams (Cg)
Cervix as a percent of body weight (C%)
Pituitary in milligrams (Pmg)
Pituitary as a percent of body weight (P%)
Left Testicle in grams (LTg)
Left Testicle as a percent of body weight (LT%)
Left Epididymis in grams (LEg)
Left Epididymis as a percent of body weight (LE%)
Left Testicle and Epididymis in grams (LTEg)
Left Testicle and Epididymis as a percent of body weight (LTE%)
Right Testicle in grams (RTg)
Right Testicle as a percent of body weight (RT%)
Right Epididymis in grams (REg)
Right Epididymis as a percent of body weight (RE%)
Right Testicle and Epididymis in grams (RTEg)
Right Testicle and Epididymis as a percent of body weight (RTE%)
Seminal Vesicle in grams (SVg)
Seminal Vesicle as a percent of body weight (SV%)
Pituitary in milligrams (Pmg)
Pituitary as a percent of body weight (P%)
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Additional data from Trial 1
Table A.1

Effects of sow treatment on female neonatal pig tissue weights.

Note: Effect of isoflavone (Novasoy 70) supplementation of sow diets starting at day
100 of gestation on wet weight of all tissue recovered from female neonatal pigs on post
natal day 14 Data is presented as LSM ± SE. Pvalue > 0.05 for all values in table
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Table A.2

Effect of neonatal pig treatment on female tissue weights.

Note: Effects of 7 days of in vivo exposure with estrogenic compounds on all tissue weights recovered from female neonatal pigs.
Genistein was administered orally at 3 mg/kg or 9 mg/kg and estradiol at 50 µg/kg body weight/day. Data is presented as LSM ±
SE. Pvalue < 0.05 represented by a.
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Table A.3

Effect of sow treatment by pig treatment interaction on female tissue weights.

Note: Effects of isoflavone (Novasoy 70) supplementation of sow diets starting at 100 days of gestation and in vivo treatment of
neonatal pigs from post natal day 7 to day 14 on tissue weights recovered from female neonatal pigs. Genistein was administered
orally at 3 mg/kg or 9 mg/kg and estradiol at 50 µg/kg body weight/day. Data is presented as LSM ± SE.
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Table A.4

Effect of sow treatment on male tissue weights.

Note: Effect of isoflavone (Novasoy 70) supplementation of sow diets starting at day
100 of gestation on wet weight of all tissue recovered from male neonatal pigs on post
natal day 14. Data is presented as LSM ± SE.
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Table A.5

Effect of neonatal pig treatment on male tissue weights.

Note: Effects of 7 days of in vivo exposure with estrogenic compounds on all tissue weights recovered from male neonatal pigs.
Genistein was administered orally at 3 mg/kg or 9 mg/kg and estradiol at 50 µg/kg body weight/day. Data is presented as LSM ±
SE.
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Table A.6

Effect of sow treatment by pig treatment interaction on male tissue weights.

Note: Effects of isoflavone (Novasoy 70) supplementation of sow diets starting at 100 days of gestation and in vivo treatment of
neonatal pigs from post natal day 7 to day 14 on tissue weights recovered from male neonatal pigs. Genistein was administered
orally at 3 mg/kg or 9 mg/kg and estradiol at 50 µg/kg body weight/day. Data is presented as LSM ± SE. P value > 0.05 for all
values in table.
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Additional data from Trial 2
Table A.7

Effect of sow treatment on female tissue weights.

Note: Effect of isoflavone (Novasoy 70) supplementation of sow diets starting at day
100 of gestation on wet weight of all tissue recovered from female neonatal pigs on post
natal day 14.
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Table A.8

Effect of neonatal pig treatment on female tissue weights.

Note: Effects of 7 days of in vivo exposure with estrogenic compounds on all tissue weights recovered from female neonatal pigs.
Genistein was administered orally at 3 mg/kg or 9 mg/kg and estradiol at 50 µg/kg body weight/day. Data is presented as LSM ±
SE.
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Table A.9

Effect of sow treatment by pig treatment interaction on female tissue weight.

Note: Effects of isoflavone (Novasoy 70) supplementation of sow diets starting at 100 days of gestation and in vivo treatment of
neonatal pigs from post natal day 7 to day 14 on tissue weights recovered from female neonatal pigs. Genistein was administered
orally at 3 mg/kg or 9 mg/kg and estradiol at 50 µg/kg body weight/day. Data is presented as LSM ± SE. P value > 0.05 for all
values in table.
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Table A.10 Effect of sow treatment on male tissue weights.

Note: Effect of isoflavone (Novasoy 70) supplementation of sow diets starting at day
100 of gestation on wet weight of all tissue recovered from male neonatal pigs on post
natal day 14. Data is presented as LSM ± SE.
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Table A.11 Effect of neonatal pig treatment on male tissue weights.

Note: Effects of 7 days of in vivo exposure with estrogenic compounds on all tissue weights recovered from male neonatal pigs.
Genistein was administered orally at 3 mg/kg or 9 mg/kg and estradiol at 50 µg/kg body weight/day. Data is presented as LSM ±
SE.
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Table A.12 Effect of sow treatment by pig treatment interaction on male tissue weights.

Note: Effects of isoflavone (Novasoy 70) supplementation of sow diets starting at 100 days of gestation and in vivo treatment of
neonatal pigs from post natal day 7 to day 14 on tissue weights recovered from male neonatal pigs. Genistein was administered
orally at 3 mg/kg or 9 mg/kg and estradiol at 50 µg/kg body weight/day. Data is presented as LSM ± SE. P value > 0.05 for all
values in table.
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Additional figures from Trial 1

Figure A.1

Effect of sow treatment by neonatal pig treatment on female neonatal
pituitary as a percent of body weight.

Note: Effects of isoflavone (Novasoy 70) supplementation of sow diets starting at 100
days of gestation and in vivo treatment of female neonatal pigs from post natal day 7 to
day 14 on wet weight of the pituitary gland. Genistein was administered orally at 3
mg/kg or 9 mg/kg and estradiol at 50 µg/kg body weight/day. Data is presented as LSM
± SE.
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Figure A.2

Effect of neonatal pig treatment on neonatal pig uterus as a percent of body
weight.

Note: Effects of 7 days of in vivo exposure with estrogenic compounds on uterine tissue
weights recovered from neonatal pigs. Genistein was administered orally at 3 mg/kg or 9
mg/kg and estradiol at 50 µg/kg body weight/day. Data is presented as LSM ± SE.
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Figure A.3

Effect of neonatal pig treatment on neonatal pig uterus weight.

Note: Effects of 7 days of in vivo exposure with estrogenic compounds on uterine tissue
weights recovered from neonatal pigs. Genistein was administered orally at 3 mg/kg or 9
mg/kg and estradiol at 50 µg/kg body weight/day. Data is presented as LSM ± SE
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Figure A.4

Effect of neonatal pig treatment on neonatal pig cervix weight.

Note: Effects of 7 days of in vivo exposure with estrogenic compounds on cervix tissue
weights recovered from neonatal pigs. Genistein was administered orally at 3 mg/kg or 9
mg/kg and estradiol at 50 µg/kg body weight/day. Data is presented as LSM ± SE
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Figure A.5

Effect of sow treatment by neonatal pig treatment interaction on neonatal
pig cervix as a percent of body weight.

Note: Effects of isoflavone (Novasoy 70) supplementation of sow diets starting at 100
days of gestation and in vivo treatment of female neonatal pigs from post natal day 7 to
day 14 on cervix weights as a percent of body weights recovered from neonatal pigs.
Genistein was administered orally at 3 mg/kg or 9 mg/kg and estradiol at 50 µg/kg body
weight/day. Data is presented as LSM ± SE.
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Figure A.6

Effect of neonatal pig treatment on neonatal pig reproductive tract weight.

Note: Effects of 7 days of in vivo exposure with estrogenic compounds on reproductive
tract tissue weights recovered from neonatal pigs. Genistein was administered orally at 3
mg/kg or 9 mg/kg and estradiol at 50 µg/kg body weight/day. Data is presented as LSM ±
SE.
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Figure A.7

Effect of neonatal pig treatment on neonatal pig reproductive tract weight
as a percent of body weight.

Note: Effects of 7 days of in vivo exposure with estrogenic compounds on reproductive
tract tissue weights as a percent of body weights recovered from neonatal pigs. Genistein
was administered orally at 3 mg/kg or 9 mg/kg and estradiol at 50 µg/kg body
weight/day. Data is presented as LSM ± SE.
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Figure A.8

Effect of neonatal pig treatment on neonatal pig seminal vesicle as a
percent of body weight.

Note: Effects of 7 days of in vivo exposure with estrogenic compounds on seminal
vesicle tissue weights as a percent of body weights recovered from neonatal pigs.
Genistein was administered orally at 3 mg/kg or 9 mg/kg and estradiol at 50 µg/kg body
weight/day. Data is presented as LSM ± SE.
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Figure A.9

Effect of sow treatment on neonatal pig right testicle weight.

Note: Effect of isoflavone (Novasoy 70) supplementation of sow diets starting at day
100 of gestation on wet weight of the right testicle recovered from neonatal pigs on post
natal day 14. Data is presented as LSM ± SE.
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Figure A.10 Effect of sow treatment on neonatal pig left testicle weight.
Note: Effect of isoflavone (Novasoy 70) supplementation of sow diets starting at day
100 of gestation on wet weight of the left testicle recovered from neonatal pigs on post
natal day 14. Data is presented as LSM ± SE
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Figure A.11 Effect of sow treatment on neonatal pig right testicle as a percent of body
weight.
Note: Effect of isoflavone (Novasoy 70) supplementation of sow diets starting at day
100 of gestation on wet weight of the right testicle recovered from neonatal pigs on post
natal day 14. Data is presented as LSM ± SE.
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Figure A.12 Effect of sow treatment on neonatal pig left testicle as a percent of body
weight.
Note: Effect of isoflavone (Novasoy 70) supplementation of sow diets starting at day
100 of gestation on wet weight of the left testicle recovered from neonatal pigs on post
natal day 14. Data is presented as LSM ± SE
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Figure A.13 Effect of sow treatment on neonatal pig right testicle and epididymis
weight.
Note: Effect of isoflavone (Novasoy 70) supplementation of sow diets starting at day
100 of gestation on combined wet weight of the right testicle and epididymis recovered
from neonatal pigs on post natal day 14. Data is presented as LSM ± SE.
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Figure A.14 Effect of sow treatment on neonatal pig right testicle and epididymis as a
percent of body weight.
Note: Effect of isoflavone (Novasoy 70) supplementation of sow diets starting at day
100 of gestation on combined wet weight as a percent of body weight of the right testicle
and epididymis recovered from neonatal pigs on post natal day 14. Data is presented as
LSM ± SE.
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Figure A.15 Effect of sow treatment on neonatal pig left testicle and epididymis weight.
Note: Effect of isoflavone (Novasoy 70) supplementation of sow diets starting at day
100 of gestation on combined wet weight of the left testicle and epididymis recovered
from neonatal pigs on post natal day 14. Data is presented as LSM ± SE.
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Figure A.16 Effect of sow treatment on neonatal pig left testicle and epididymis as a
percent of body weight.
Note: Effect of isoflavone (Novasoy 70) supplementation of sow diets starting at day
100 of gestation on combined wet weight as a percent of body weight of the left testicle
and epididymis recovered from neonatal pigs on post natal day 14. Data is presented as
LSM ± SE.
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Additional figures from Trial 2

Figure A.17 Effect of neonatal pig treatment on neonatal pig right ovary.
Note: Effects of 7 days of in vivo exposure with estrogenic compounds on right ovary
tissue weights recovered from neonatal pigs. Genistein was administered orally at 3
mg/kg or 9 mg/kg and estradiol at 50 µg/kg body weight/day. Data is presented as LSM ±
SE.
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Figure A.18 Effect of neonatal pig treatment on neonatal pig right ovary as a percent of
body weight.
Note: Effects of 7 days of in vivo exposure with estrogenic compounds on right ovary
tissue weights recovered from neonatal pigs. Genistein was administered orally at 3
mg/kg or 9 mg/kg and estradiol at 50 µg/kg body weight/day. Data is presented as LSM ±
SE.
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Figure A.19 Effect of neonatal pig treatment on neonatal pig left ovary as a percent of
body weight.
Note: Effects of 7 days of in vivo exposure with estrogenic compounds on left ovary
tissue weights recovered from neonatal pigs. Genistein was administered orally at 3
mg/kg or 9 mg/kg and estradiol at 50 µg/kg body weight/day. Data is presented as LSM ±
SE.
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Figure A.20 Effect of neonatal pig treatment on neonatal pig right and left ovary weight.
Note: Effects of 7 days of in vivo exposure with estrogenic compounds on combined
right and left ovary tissue weights recovered from neonatal pigs. Genistein was
administered orally at 3 mg/kg or 9 mg/kg and estradiol at 50 µg/kg body weight/day.
Data is presented as LSM ± SE
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Figure A.21 Effect of neonatal pig treatment on neonatal pig right and left ovary as a
percent of body weight.
Note: Effects of 7 days of in vivo exposure with estrogenic compounds on right and left
ovary tissue weights recovered from neonatal pigs. Genistein was administered orally at 3
mg/kg or 9 mg/kg and estradiol at 50 µg/kg body weight/day. Data is presented as LSM ±
SE
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Figure A.22 Effect of neonatal pig treatment on neonatal pig uterus weight.
Note: Effects of 7 days of in vivo exposure with estrogenic compounds on uterine tissue
weights recovered from neonatal pigs. Genistein was administered orally at 3 mg/kg or 9
mg/kg and estradiol at 50 µg/kg body weight/day. Data is presented as LSM ± SE
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Figure A.23 Effect of neonatal pig treatment on neonatal pig uterus as a percent of body
weight.
Note: Effects of 7 days of in vivo exposure with estrogenic compounds on uterine tissue
weights recovered from neonatal pigs. Genistein was administered orally at 3 mg/kg or 9
mg/kg and estradiol at 50 µg/kg body weight/day. Data is presented as LSM ± SE
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Figure A.24 Effect of neonatal pig treatment on neonatal pig cervix weight.
Note: Effects of 7 days of in vivo exposure with estrogenic compounds on cervix tissue
weights recovered from neonatal pigs. Genistein was administered orally at 3 mg/kg or 9
mg/kg and estradiol at 50 µg/kg body weight/day. Data is presented as LSM ± SE
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Figure A.25 Effect of neonatal pig treatment on neonatal pig cervix as a percent of body
weight.
Note: Effects of 7 days of in vivo exposure with estrogenic compounds on cervix tissue
weights recovered from neonatal pigs. Genistein was administered orally at 3 mg/kg or 9
mg/kg and estradiol at 50 µg/kg body weight/day. Data is presented as LSM ± SE.
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Figure A.26 Effect of neonatal pig treatment on neonatal pig reproductive tract weight.
Note: Effects of 7 days of in vivo exposure with estrogenic compounds on reproductive
tract tissue weights recovered from neonatal pigs. Genistein was administered orally at 3
mg/kg or 9 mg/kg and estradiol at 50 µg/kg body weight/day. Data is presented as LSM ±
SE.
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Figure A.27 Effect of neonatal pig treatment on neonatal pig reproductive tract as a
percent of body weight.
Note: Effects of 7 days of in vivo exposure with estrogenic compounds on reproductive
tract tissue weights recovered from neonatal pigs. Genistein was administered orally at 3
mg/kg or 9 mg/kg and estradiol at 50 µg/kg body weight/day. Data is presented as LSM ±
SE.
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